Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: A randomized controlled trial

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Chen, Zhangjing ^a   Wu, Jufang ^a   Zhang, Yingyuan ^a   Wei, Junming ^b   Leng, Xisheng ^c   Bi, Jianwei ^d   Li, Rong ^e   Yan, Lunan ^f   Quan, Zhiwei ^g   Chen, Xiaoping ^h   Yu, Yunsong ⁱ   Wu, Zhiyong ^j   Liu, Dawei ^k   Ma, Xiaochun ^l   Maroko, Robert ^m   Cooper, Angel ^m  

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f SICHUAN UNIVERSITY   (China)

^g XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h Tongji Hospital   (China)

ⁱ ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^j SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^k PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^l CHINA MEDICAL UNIVERSITY   (China)

^m PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; CILASTATIN; CILASTATIN, IMIPENEM DRUG COMBINATION; DRUG DERIVATIVE; IMIPENEM; MINOCYCLINE;

ABDOMINAL DISTENSION; ABDOMINAL INFECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING DISORDER; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALING; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOPROTEINEMIA; MAJOR CLINICAL STUDY; MALE; MONOCYTOSIS; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SHOCK; SIDE EFFECT; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; VOMITING; AGED; ASIAN; BACTERIAL INFECTION; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; PERITONITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BACTERIAL INFECTIONS; CILASTATIN; DRUG COMBINATIONS; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; MINOCYCLINE; PERITONITIS; TREATMENT OUTCOME;

EID: 77954684523     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-217     Document Type: Article

References (24)

1. Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, Yowler C. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002, 3(3):175-233. 10.1089/109629602761624180, 12542923.
2. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003, 37(8):997-1005. 10.1086/378702, 14523762.
3. Weigelt JA. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med 2007, 74(Suppl 4):S29-37. 10.3949/ccjm.74.Suppl_4.S29, 17847176.
4. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998, 22(2):158-163. 10.1007/s002689900364, 9451931.
5. Krobot K, Yin D, Zhang Q, Sen S, Altendorf-Hofmann A, Scheele J, Sendt W. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004, 23(9):682-687. 10.1007/s10096-004-1199-0, 15322931.
6. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003, 31(8):2228-2237. 10.1097/01.CCM.0000087326.59341.51, 12973184.
7. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006, 43(4):518-524. 10.1086/505494, 16838243.
8. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 2002, 5(3-4):119-125. 10.1016/S1368-7646(02)00051-1, 12237079.
9. Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008, 60(4):421-427.
10. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005, 52(3):215-227. 10.1016/j.diagmicrobio.2005.06.001, 16105567.
11. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006, 4(1):9-25. 10.1586/14787210.4.1.9, 16441206.
12. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52(2):570-573. 10.1128/AAC.01114-07, 2224761, 18070960.
13. Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008, 54(2):91-100. 10.1159/000118660, 18303257.
14. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005, 52(3):209-213. 10.1016/j.diagmicrobio.2005.06.010, 16105566.
15. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005, 41(Suppl 5):S333-340. 10.1086/431674, 16080071.
16. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354-367. 10.1086/431676, 16080073.
17. Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005, 9(5):348-356. 10.1590/S1413-86702005000500001, 16410885.
18. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005, 52(3):203-208. 10.1016/j.diagmicrobio.2005.05.002, 16105565.
19. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61(3):329-338. 10.1016/j.diagmicrobio.2008.04.009, 18508226.
20. Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, Ellis-Grosse E, Loh E, . Three Hundred Six Study G Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005, 3(1):35-47. 10.1016/j.ijsu.2005.03.011, 17462257, Three Hundred Six Study G.
21. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49(11):4658-4666. 10.1128/AAC.49.11.4658-4666.2005, 1280174, 16251309.
22. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005, 9(5):251-261. 10.1016/j.ijid.2005.05.003, 16099700.
23. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341-353. 10.1086/431675, 16080072.
24. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005, 49(1):220-229. 10.1128/AAC.49.1.220-229.2005, 538906, 15616299.